Advanced gallbladder cancer, HER2+++

After months in the hospital, my father finally received zanidatamab.
We had followed this drug on DengYueMed for over a year.

The timing was cruel. The fever reaction was strong.
But today, he felt better, ate more, and asked for dinner.

Sometimes hope isn’t a response rate.
Sometimes it’s simply getting through the day.

#CancerCare #HER2 #GallbladderCancer #Caregiver #Zanidatamab #DengYueMed

¿Qué es el HER2?

Conoce más sobre este tema en nuestro evento sobre Terapias Dirigidas de Cáncer de Pulmón 2025.

#cáncerdepulmón #HER2 #EGFR

🔬 Can AI help decode how antibodies recognize cancer-related proteins like HER2?

🔗 Investigating and evaluating potential antigen binding sites for monoclonal anti-HER2 antibodies: The LightDock approach. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.06.001

📚 CSBJ: https://www.csbj.org/

#HER2 #CancerResearch #MonoclonalAntibodies #LightDock #AlphaFold #Bioinformatics #MolecularDocking #InSilicoBiology #ComputationalBiology #AntibodyResearch #StructuralBiology

A recently developed ⭐️#cancer #vaccine for dogs⭐️ is showing promising results in clinical trials, which have been running since 2016, and there's hope that some of the benefits of the vaccine could be translated into human cancer treatments.

More than 300 dogs have been treated with the vaccine to date, and the twelve--month survival rate for canines with certain cancers has been lifted from about 35 percent to 60 percent. Tumors in many of the animals have also shrunk.

Known officially as the #Canine #EGFR/#HER2 #Peptide #Cancer #Immunotherapeutic, the treatment grew out of studies of autoimmune diseases, where the immune system damages the body's own tissue rather than any invading threats.
The vaccine is designed to get the immune system to attack cancer instead.

In many ways tumors are like the targets of autoimmune diseases," says rheumatologist #Mark #Mamula, from the Yale University School of Medicine.

"Cancer cells are your own tissue and are attacked by the immune system. The difference is we want the immune system to attack a tumor."

As outlined in a 2021 study by Mamula and colleagues, the treatment gets the immune cells to produce antibody defenses, which attach themselves to tumors and interfere with their growth patterns.

Specifically, these antibodies hunt down two proteins: 🔸epidermal growth factor receptor 🔸( #EGFR ) and 🔸human epidermal growth factor receptor 2🔸 ( #HER2 ).

Mutations causing overexpression of these proteins drive uncontrolled cell division in some human and canine cancers.

https://www.sciencealert.com/breakthrough-cancer-vaccine-for-dogs-is-truly-revolutionary-scientist-says

#TumorBoardTuesday

🔬🧬@DrTeplinksy took us through paradigm-shifting therapy in #HER2 low #metastaticbreastcancer.

➡️Here’s the Case 🎀

👉 🆓 #CME credit by answering 2 quick ❓
ALL CME 🔗: http://integrityce.com/tbt

CME eval🔗: http://integrityce.com/tbteval

Thank you @drteplinsky for an engaging #TumorBoardTuesday! Exciting to see how the treatment of #HER2 low disease is changing.

Watch for a special Friday ed of wrap up. To get ready, try your 👋🏼at the ❓s for free #CME!

---
RT @drteplinsky
#PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval🔗 http://integrityce.com/tbtEval

🤔@drteplinsky taught us progress of HER2+ low #breastcancer
🤨What would U pick for 60y👩🏻
ER+/PR-/HER2-low mBC
recent …
https://twitter.com/drteplinsky/status/1623139634694787073

"In the last 20 years, numerous other HER2-targeted therapies have proven successful in the metastatic, adjuvant and neoadjuvant settings, including another monoclonal antibody — pertuzumab — three separate tyrosine kinase inhibitors — lapatinib, neratinib, and tucatinib — and two antibody drug conjugates (ADCs) — ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan (TDx-D)."

#BreastCancer #her2

https://www.jci.org/articles/view/166384